Form 4: IMMUNIC, INC. Director Acquires Stock Options

IMMUNIC, INC. reports that Director Simona Skerjanec acquired 25,370 stock options on June 29, 2026, as part of a plan approved by the Board and stockholders.

Summary

• Simona Skerjanec, a Director at IMMUNIC, INC., acquired 25,370 stock options on June 29, 2026.
• These options are for the purchase of common stock at an exercise price of $10.90 per share.
• The acquisition was made under a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The options were conditionally approved by the Board of Directors on March 27, 2026, and subsequently approved by stockholders at the 2026 Annual Meeting on June 29, 2026.
• The options are fully vested as of March 27, 2026, and have an expiration date of March 27, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard stock option grant to a director under an approved plan, indicating ongoing incentive alignment rather than a significant new development.

Positives

• Director Simona Skerjanec has acquired a significant number of stock options, indicating confidence in the company's future.
• The acquisition was made under a Rule 10b5-1(c) plan, suggesting a pre-determined and structured approach to trading.
• The options are fully vested, meaning they can be exercised immediately if desired.

Negatives

• The filing does not disclose the specific reason for the acquisition beyond the standard plan approval process.

Risks

• The value of the acquired stock options is subject to the future performance of IMMUNIC, INC.'s stock price.
• Potential dilution to existing shareholders if a large number of options are exercised.

Future Outlook

The acquisition of stock options by a director, under a plan approved by both the board and stockholders, suggests a positive outlook on the company's future prospects and stock value.

Management Comments

• The options were conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders.
• Stockholder approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.
• The option is fully vested as of March 27, 2026.

Industry Context

StockSavvy.ai notes that the granting and acquisition of stock options by company directors is a common practice in the biotechnology and pharmaceutical sectors, often used as a long-term incentive to align management's interests with those of shareholders.

Corporate Governance

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be seen as a positive sign of management's commitment and belief in the company's future value. However, the potential exercise of these options could lead to dilution.
• Employees: The approval of the equity incentive plan amendment suggests continued opportunities for equity-based compensation for employees.
• Management: Directors and officers are incentivized to perform well to increase the value of their stock options.

Next Steps

• The options are exercisable until their expiration date of March 27, 2036.
• Further transactions by Simona Skerjanec will be reported on subsequent SEC filings.

Key Dates

Keywords

IMMUNIC, INC., IMUX, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act, Rule 10b5-1(c), Equity Incentive Plan